CAR T-Cell Therapy: Hope and Healing in the Battle Against Cancer

Abstract

With numerous forms and a myriad of genetic and environmental factors, cancer continues to be a leading cause of morbidity and mortality worldwide. Advances in cancer research have led to a deeper understanding of the molecular mechanisms driving cancer progression, facilitating the development of targeted therapies and immunotherapies. Chimeric Antigen Receptor T-cell therapy, commonly known as CAR T-cell therapy, represents a groundbreaking approach in the field of cancer immunotherapy. This innovative treatment involves genetically engineering a patient's T cells to express chimeric antigen receptors (CARs) that target specific cancer cells. CAR-T therapy has demonstrated remarkable success in the treatment of certain hematologic malignancies, particularly B-cell malignancies like acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), and non-Hodgkin lymphoma (NHL). CAR T-cell therapy also has challenges, such as managing side effects like cytokine release syndrome and neurotoxicity, high treatment costs, and the need for further research to broaden its applicability to solid tumours. CAR T-cell therapies, such as Kymriah and Yescarta, have demonstrated impressive clinical outcomes in patients with relapsed or refractory cancers, offering hope for those with limited treatment options. Additionally, the long-term durability of responses requires continuous monitoring and research.